523 related articles for article (PubMed ID: 10488335)
1. Reversible tumorigenesis by MYC in hematopoietic lineages.
Felsher DW; Bishop JM
Mol Cell; 1999 Aug; 4(2):199-207. PubMed ID: 10488335
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice.
Kobzdej M; Matuszyk J; Strzadala L
Leuk Res; 2000 Jan; 24(1):33-8. PubMed ID: 10634643
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice.
Blyth K; Stewart M; Bell M; James C; Evan G; Neil JC; Cameron ER
Oncogene; 2000 Feb; 19(6):773-82. PubMed ID: 10698495
[TBL] [Abstract][Full Text] [Related]
4. MYC levels govern hematopoietic tumor type and latency in transgenic mice.
Smith DP; Bath ML; Metcalf D; Harris AW; Cory S
Blood; 2006 Jul; 108(2):653-61. PubMed ID: 16537801
[TBL] [Abstract][Full Text] [Related]
5. Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Jain M; Arvanitis C; Chu K; Dewey W; Leonhardt E; Trinh M; Sundberg CD; Bishop JM; Felsher DW
Science; 2002 Jul; 297(5578):102-4. PubMed ID: 12098700
[TBL] [Abstract][Full Text] [Related]
6. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.
Karlsson A; Giuriato S; Tang F; Fung-Weier J; Levan G; Felsher DW
Blood; 2003 Apr; 101(7):2797-803. PubMed ID: 12517816
[TBL] [Abstract][Full Text] [Related]
7. The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo.
Andreasson P; Schwaller J; Anastasiadou E; Aster J; Gilliland DG
Cancer Genet Cytogenet; 2001 Oct; 130(2):93-104. PubMed ID: 11675129
[TBL] [Abstract][Full Text] [Related]
8. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
9. Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region.
Stewart M; Cameron E; Campbell M; McFarlane R; Toth S; Lang K; Onions D; Neil JC
Int J Cancer; 1993 Apr; 53(6):1023-30. PubMed ID: 8473043
[TBL] [Abstract][Full Text] [Related]
10. Rehabilitation of cancer through oncogene inactivation.
Shachaf CM; Felsher DW
Trends Mol Med; 2005 Jul; 11(7):316-21. PubMed ID: 15955741
[TBL] [Abstract][Full Text] [Related]
11. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
12. MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation.
Schreiner S; Birke M; García-Cuéllar MP; Zilles O; Greil J; Slany RK
Cancer Res; 2001 Sep; 61(17):6480-6. PubMed ID: 11522644
[TBL] [Abstract][Full Text] [Related]
13. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc.
Haupt Y; Harris AW; Adams JM
Oncogene; 1992 May; 7(5):981-6. PubMed ID: 1570158
[TBL] [Abstract][Full Text] [Related]
14. Conditional transgenic models define how MYC initiates and maintains tumorigenesis.
Arvanitis C; Felsher DW
Semin Cancer Biol; 2006 Aug; 16(4):313-7. PubMed ID: 16935001
[TBL] [Abstract][Full Text] [Related]
15. Uncovering MYC's full oncogenic potential in the hematopoietic system.
Janz S
Oncogene; 2005 May; 24(22):3541-3. PubMed ID: 15782131
[TBL] [Abstract][Full Text] [Related]
16. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc.
Allen JD; Verhoeven E; Domen J; van der Valk M; Berns A
Oncogene; 1997 Sep; 15(10):1133-41. PubMed ID: 9294606
[TBL] [Abstract][Full Text] [Related]
17. Reversible lymphomagenesis in conditionally c-MYC expressing mice.
Marinkovic D; Marinkovic T; Mahr B; Hess J; Wirth T
Int J Cancer; 2004 Jun; 110(3):336-42. PubMed ID: 15095297
[TBL] [Abstract][Full Text] [Related]
18. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
Choi PS; van Riggelen J; Gentles AJ; Bachireddy P; Rakhra K; Adam SJ; Plevritis SK; Felsher DW
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17432-7. PubMed ID: 21969595
[TBL] [Abstract][Full Text] [Related]
19. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss.
Blyth K; Terry A; O'Hara M; Baxter EW; Campbell M; Stewart M; Donehower LA; Onions DE; Neil JC; Cameron ER
Oncogene; 1995 May; 10(9):1717-23. PubMed ID: 7753548
[TBL] [Abstract][Full Text] [Related]
20. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
